The company, which is now the world’s third largest manufacturer of generic drugs, has launched a new global website.
Actavis now has two business strands: Actavis Pharma makes and sells generic and biosimilar medicines while Actavis Specialty Brands makes and sells branded drugs in specialist areas.
The company, which has operations in 60 countries worldwide, achieved $8bn revenue in 2012.
Paul Bisaro, President and CEO of Actavis, said: “Today marks an historic day for Actavis and a milestone in our evolution into a global pharmaceutical leader. While we have been operating as one company since last year, today we unite all of our 17,000 employees under a single name.”
The new Actavis logo was designed by Lippincott, a leading brand development agency. The company’s press release explains that its green colour “reflects growth – a fundamental foundation for Actavis and its future – and a commitment to be an environmentally responsible company.”
Actavis is based in New Jersey, USA, with international headquarters in Zug, Switzerland. Its UK operation is based in Barnstaple, Devon.
The company’s Actavis Pharma business manufactures and sells generic, branded generic and legacy brands and OTC products, and is ranked in the top 10 in 33 global markets.
Its Actavis Specialty Brands business manufactures and sells a portfolio of about 40 products with applications in urology and women’s health.